
In 2015 was created LifeForce Capital, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the San Francisco.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the LifeForce Capital, startups are often financed by First Round Capital, Oak Investment Partners, Nexus Venture Partners. The meaningful sponsors for the fund in investment in the same round are Threshold, Joel Ayala, Oak HC/FT. In the next rounds fund is usually obtained by SR One, Kaszek Ventures, Y Combinator.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2018. The fund is constantly included in 2-6 deals per year. The average startup value when the investment from LifeForce Capital is 500 millions - 1 billion dollars. This LifeForce Capital works on 24 percentage points less the average amount of lead investments comparing to the other organizations.
The fund was created by John Noonan. The overall number of key employees were 2.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Clover Health, HeartFlow, One Medical. Among the most popular fund investment industries, there are Medical, Health Diagnostics. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
Fund Name | Location |
Akron Archangels | Akron, Ohio, United States |
Blumenstein/Thorne Information Partners | Illinois, Lake Forest, United States |
Chukyo TV | Aichi Prefecture, Japan, Nagoya |
Columbia Entrepreneurship | New York, New York, United States |
Coppel Capital | Culiacán, Mexico, Sinaloa |
Darling Ventures | California, San Francisco, United States |
Gingerace Capital Partners | Dubai, United Arab Emirates |
HMV Group | England, London, United Kingdom |
LANXESS | Cologne, Germany, Nordrhein-Westfalen |
Mimecast | - |
Nextel Communications | Kansas, Overland Park, United States |
Omnicell | California, Mountain View, United States |
Pagoda Investment | Beijing, Beijing, China |
Phoenix Finance | Beijing, Beijing, China |
Shanghai Creation Investment | China, Shanghai |
Taize Asset Management | China, Hangzhou, Zhejiang |
TLSK Capital, LP. | - |
Vector Media | New York, New York, United States |
Woomi construction corporation | - |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Ochre Bio | $30M | 10 Oct 2022 | Oxford, England, United Kingdom | ||
Transition Bio | $50M | 02 Jun 2022 | Cambridge, Massachusetts, United States | ||
MindRight Health | $1M | 24 May 2022 | Newark, New Jersey, United States | ||
Clover Therapeutics | $18M | 17 May 2022 | Jersey City, New Jersey, United States | ||
Aspen Neuroscience | $147M | 09 May 2022 | San Diego, California, United States | ||
Vivante Health | $16M | 08 Mar 2022 | Houston, Texas, United States | ||
Synapticure | $6M | 02 Feb 2022 | Chicago, Illinois, United States | ||
64-x | $55M | 19 Jan 2022 | San Francisco, California, United States | ||
PostEra | $24M | 11 Jan 2022 | San Francisco, California, United States |
– Fauna Bio is an Emeryville, California-based biotechnology company leveraging animal genomics to improve human health.
– The company raised $9m in Seed funding.
– The round was led by LifeForce Capital with participation from True Ventures, Boom Capital, Pacific 8 Ventures, BioMed Ventures, Vibe Capital and Arcadia Science.
– The new investment will be used to expand its drug discovery platform Convergence while accelerating the discovery of new therapeutic targets for human diseases across a broad range of indications.
– Enveda Biosciences announced an oversubscribed $51M Series A funding round.
– The financing was led by Lux Capital with participation from Two Sigma Ventures, Hummingbird VC, Catalio Capital, Lifeforce Capital, and Matthew De Silva of Notable Labs along with existing investors True Ventures, Wireframe Ventures, Village Global, and Chris Gibson of Recursion.
– Nature is the greatest source of therapeutics we know, yet 95 percent of the natural world is a chemical mystery. Enveda is systematically exploring this unknown space to unlock its potential for new medicines with the first high-resolution chemical map of the natural world.
– This new investment will further power Enveda’s data-driven approach to screening, validating, and developing high-potential natural compounds into first-in-class clinical candidates.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Ochre Bio | $30M | 10 Oct 2022 | Oxford, England, United Kingdom | ||
Transition Bio | $50M | 02 Jun 2022 | Cambridge, Massachusetts, United States | ||
MindRight Health | $1M | 24 May 2022 | Newark, New Jersey, United States | ||
Clover Therapeutics | $18M | 17 May 2022 | Jersey City, New Jersey, United States | ||
Aspen Neuroscience | $147M | 09 May 2022 | San Diego, California, United States | ||
Vivante Health | $16M | 08 Mar 2022 | Houston, Texas, United States | ||
Synapticure | $6M | 02 Feb 2022 | Chicago, Illinois, United States | ||
64-x | $55M | 19 Jan 2022 | San Francisco, California, United States | ||
PostEra | $24M | 11 Jan 2022 | San Francisco, California, United States |